Noerr advises Meihua Holdings on acquiring Kyowa Hakko Bio’s amino acids and HMO business

Noerr has comprehensively advised Meihua Holdings Group Co., Ltd. (SHSE: 600873) on acquiring the amino acids and human milk oligosaccharide (HMO) business of the Japanese company Kyowa Hakko Bio Co., Ltd. Closing has already occurred.

The Noerr team led by partners Georg Schneider and Sebastian Voigt supported Meihua Holdings by conducting the legal due diligence of the seller’s German subsidiary Kyowa Hakko Europe GmbH, negotiating the local transfer agreement, executing the closing and subsequent post-merger integration steps.

For Meihua, the acquisition marks an important strategic milestone. The transaction significantly broadens its product portfolio in pharmaceutical amino acids and human milk oligosaccharides, while also providing access to advanced fermentation technologies, expanded production capacities and extensive regulatory approvals. This will further strengthen Meihua’s international market position with operations across Asia, Europe and North America.

Advisors to Meihua Holdings: Noerr Partnerschaftsgesellschaft mbB

Lead: Georg Schneider, Sebastian Voigt (both partners, Private Equity & Venture Capital)

Corporate/M&A: Julia Hecht (senior associate, Private Equity)

Product Regulation: Evelyn Schulz (partner), Isabell Jakobs (associated partner), Theresa Möller (senior associate)

Employment: Daniel Dommermuth (associated partner)